Table 2.

Summary of active clinical trials investigating amyotrophic lateral sclerosis in relation to oxidative stress. The studies have been retrieved from clinicaltrials.gov with search keywords “Condition or disease = Amyotrophic lateral sclerosis” and “Other terms = oxidative stress” and selecting the items with the status “Recruiting” and “Active, not recruiting”.

ClinicalTrials.gov Identifier	Official Title	Intervention/ Treatment	Phase	Estimated Completion Date	Ref.
NCT04788745	Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS	Drug: Trimetazidine Dihydrochloride	Phase 2	31 March 2023	[35]
NCT04097158	Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone	Other: Sample Collection	Not applicable	September 2023	[36]
NCT03293069	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone	Drug: Deferiprone Drug: Placebo Oral Tablet	Phase 2 Phase 3	November 2023	[37]
NCT04244630	Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial	Combination Product: Antioxidants	Phase 2	December 2023	[38]
NCT04259255	Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)	Drug: Edaravone	Not applicable	March 2023	[39]